Perspective Therapeutics, Inc. · AMEX:CATX
Perspective Therapeutics — Investor Day (March 2024)
100 slides from Perspective Therapeutics's investor day presentation, Mar 19, 2024
Slide 1: Analyst Day Presentation
PERSPECTiVE THERAPEUTICS Analyst Day Presentation NYSE: CATX
Slide 2: Legal Disclaimers
Legal Disclaimers This presentation contains fonacockig statéments within the meaingof the Unites States Pate Secures tigation Reform Act of 1995, Sutemertsin this presentation thatare not Statements of istoncal fact are fornorong statements Wotds suchas "may." "wi." “shoud” expect “plan,” “artpate
Slide 3: Analyst Day Agenda
Analyst Day Agenda NYSE, 18 March 2024 Introductions ] Pipeline Update | Clinical Update KOL Discussion Corporate / Manufacturing Update | Questions,
Slide 4: Management Team
ManagementTeam Deep Experience in Radiopharmaceuticalsand Oncology Drug Development Thijs Spoor Chief Execute Officer 20+ years of expertise in biotechnology ‘companies: publicand private companies ‘oncology and nuclear pharmacy Jonathan Hunt Chie Financial Officer 20+ years of expertise in financia
Slide 5: Investment Highlights
Investment Highlights Platform radiopharmaceutical company targeting pan-cancer Proprietary chelator-based peptide targeting platform ‘opportunities utilizing 2% generation «-emitter provides engine for pipeline expansion mi nanufacturingand can leverag cy logistics for broad
Slide 6: Perspective's Radiopharmaceutical Optimization Process
Perspective’s Radiopharmaceutical Optimization Process Unique Mechanism of Action Offers Pan-Cancer Opportunities Isotope Pb for SPECT imaging Targeting Peptide Pb for alpha particle therapy Linker Chelator
Slide 7: Pb-based Theranostics Enable Both Diagnosis and Targeted Treatment of Cancer
Pb-based Theranostics Enable Both Diagnosis and Targeted Treatment of Cancer Identical Distribution of Pb and “Pb for Imaging and Treatment, Respectively Cancer Cell 4 Imaging =p Targeting igang) tinker Therapeutic Patient selection Dosimetry: T, , = 52h *pb can be used to establish Pb pharmacokinet
Slide 8: Platform Expansion Engine
Platform Expansion Engine Three Lead Programs in Clinicand Broad Proprietary Pipeline Neuroendocrine cancers C ] Safety Update YMraner — varo. Meanoma (MCR) t Z sofety Update vero re , NCR PSV250 (Novel peptice) Mutiple sold tumors (== Fist in Human tages of Cncal Candidate Psv40K facoyrc) Prostate
Slide 9: Pipeline Update
Pipeline Update Clinical and Preclinical Programs
Slide 10: Pan Cancer Target: PSV359
Pan Cancer Target: PSV359 Preclinical Efficacy and First in Human Images of Novel Peptide Targeting Fibroblast Activation Protein alpha (FAP-c)
Slide 11: Fibroblast Activation Protein a is a Pan Cancer Target
Fibroblast Activation Protein a is a Pan CancerTarget Tumorstromacelisdonot FAP is primarily expressed , ‘typically express cancer- ‘on tumorstroma cells, but 5% specificmarkerslikeSSTR2 also. on somecancer cells. ‘or MCAR 5 ‘The Journal of Nuclear Medicine ‘Small molecules in development are excell
Slide 12: Fibroblast Activation Protein a is a Pan Cancer Target
Fibroblast Activation Protein a is a Pan Cancer Target* Multiple imaging products in developmentsuch as Ga-FAPi, but significanttherapeutic opportunityremains not FAP. Expression of FAP-«.on: 22 SUVns OF G2 FAI PET/CT ‘on Tumor Tumor Stroma Cols ferent Cancer Types:
Slide 13: Development of PSV359
Development of PSV359 (Discovery Phase - Optimization Phase over 12 months) In-house peptide synthesis and in vivo capabilityallows rapid iterationand optimization of novel compounds Phagedisplayscreening finitatnits | Affinity maturation Chelator/linker optimization Fibs gan ean bapeeretrs (ops 13/
Slide 14: Hit-to-lead Structure Changes that Led to Optimized Compound
Hit-to-lead Structure Changes that Led to Optimized Compound In-house peptide synthesis and in vivo capabilityallows rapid iterationand optimization of novel compounds Compound 3-30 Compound 3-42 Compound 3-59 is i i AMELESE PERE EE PAALES as OY pessererve
Slide 15: Initial Pb Candidate via Micro SPECT/CT Imaging
Initial ?°SPb] Candidate via Micro SPECT/CT Imaging Kidneys Bladder hour 3 hours 2 hours In vivo! * Good tumor uptake but could be faster + Some liver uptake * Slight kidney retention * Decision made to optimize further CC) PERSPECTIVE OY) FREE
Slide 16: Optimization: Second Pb Candidate via Micro SPECT/CT Imaging
Optimization: Second [?%°Pb] Candidate via Micro SPECT/CT Imaging In vivo Evaluation * Better tumor uptake * Little liver retention * Better kidney clearance * Decision made to optimize further to decrease kidney uptake Kidneys Livek Spleen Kidneys | Muscle [Sa " CY pensrecrve
Slide 17: Clinical Candidate Selection: PSV359 via Micro SPECT/CT Imaging
Clinical Candidate Selection: [?7Pb]PSV359 via Micro SPECT/CT Imaging 2 hours in vivo Kidneys 24 hours in vivo 24 hours ex vivo. Tumor Bm ct Ready for Clinical + ~18 months developmenttime + Over 900 million amino acid sequences initially scanned + Identified ~400 sequences for secondary evaluation
Slide 18: PSV359 via Micro SPECT/CT Imaging
[22Pb]PSV359 via Micro SPECT/CT Imaging Confirms identical biodistribution ofimaging and therapeuticisotopes (2°2Pb]Pb-PSV-359 2h in vivo 24h in vivo ad Kidneys Pb]Pb-PSV-359 CC) PERSPECTIVE OY) FREE
Slide 19: PSV359 Demonstrates Preclinical Efficacy in Human Fibrosarcoma Model
[?Pb]PSV359 Demonstrates Preclinical Efficacy in Human Fibrosarcoma Model Compares favorably against other therapeutic productsin development? & Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy 1k Zhr'9- Aeenoehe'-AneBedenbah Ane Schumann
Slide 20: Fibroblast Activation Protein a is a Pan Cancer Target
Fibroblast Activation Protein a is a Pan CancerTarget Tumorstromacelisdonot FAP is primarily expressed ‘typically express cancer- ‘on tumorstroma cells, but ‘specificmarkerslikeSSTR2 _alsoon some cancer cells. or MCaR.
Slide 21: First in Human PSV359 SPECT Imaging - Chondroblastic Osteosarcoma
Firstin Human [2°°Pb]PSV359 SPECT Imaging - Patient 1 Chondroblastic Osteosarcoma ‘ ¢. § oe) . = e ih PA Ansttute, Gurgaon, India Case3: 16 yrs/Male, Chondroblastic Osteosarcoma Injected Dose 7.2 mCi (266.4 MBq) thr Abr 4shr (anterior views) aia, OY pepsercrve
Slide 22: First in Human PSV359 SPECT Imaging - Chondroblastic Osteosarcoma
First in Human [?°°Pb]PSV359 SPECT Imaging - Patient 1 ChondroblasticOsteosarcoma Lesion in head of lefthumerus V359 SPECT/CT abr ashr CY pensrecrve
Slide 23: First in Human PSV359 SPECT Imaging - Neuroendocrine Tumor
Firstin Human [2°°Pb]PSV359 SPECT Imaging - Patient 2 Neuroendocrine Tumor a @ Case 2: 71yrs/Male, Metastatic GEP Neuroendocrine Tumor Injected Dose: 7.0 mCi (259 MBq) thr 4hr aghr (anterior views) Ate 2a [resonant pn te
Slide 24: First in Human PSV359 SPECT Imaging - Neuroendocrine Tumor
First in Human [?°°Pb]PSV359 SPECT Imaging - Patient 2 Neuroendocrine Tumor 4br 18hr A) perspecrve
Slide 25: First in Human PSV359 SPECT Imaging - Lung Adenocarcinoma
Firstin Human [2°°Pb]PSV359 SPECT Imaging - Patient 3 Lung Adenocarcinoma [2°SPb]PSV359 [®8Ga]FAPL2286 PET Case3: 51 yrs/Male, Metastatic adenocarcinoma lung Injected dose: 7.0 mCi (259 MBq) ahr 4hr 18hr (posterior views) aia ia Ate
Slide 26: First in Human PSV359 SPECT Imaging - Lung Adenocarcinoma
Firstin Human [2°°Pb]PSV359 SPECT Imaging - Patient 3 Lung Adenocarcinoma lytic lesioninsacrum PERSPECTIVE
Slide 27: First in Human PSV359 SPECT Imaging - Lung Adenocarcinoma
Firstin Human [2°°Pb]PSV359 SPECT Imaging - Patient 3 Lung Adenocarcinoma Lytic lesion in thoracic vertebra Ay ceesecrve
Slide 28: Summary - PSV359 FAP-a Program
Summary - PSV359 FAP-c: Program Potential tobe a best in-class pan-cancer targeted alpha particletherapeutic FAP-c. is a pan-cancer target that is highly expressed many cancers Perspective’s in-house discovery team has developed an optimized peptide with potential best-in-class characteristics as de
Slide 29: Preclinical Programs: Prostate Cancer
Preclinical Programs: Prostate Cancer A differentiated PSMA-targeted radiohybrid molecule for dual PET imaging and targeted alpha therapy A
Slide 30: Prostate Cancer Program: PSV40X
Prostate Cancer Program: PSV40X A differentiated PSMA-targeted radiohybrid molecule for dual PET imaging and targeted alpha therapy PSMA is a clinically and commercially validated target for radioligand therapy Diagnostic Linker Combines two chelator th single targeting ligand to provide identical d
Slide 31: PSV40X: Improved Preclinical Metrics for a Superior Therapeutic Window
PSV40xX: Improved Preclinical Metrics for a Superior Therapeutic Window in Prostate Cancer PSV404 (designated NSN24901 by Mayo Clinic) shows promise in preclinicalsetting Comparison of Uptake of [°°Ga]PSMA-11 and [*CulPSV404 ("NSN24901") in Tumor, Kidney and Salivary Gland of LNCaP Tumor Athymic Nud
Slide 32: Preclinical Programs: Pre-targeting Platform
Preclinical Programs: Pre-targeting Platform The Next Generation of Targeted Alpha Particle Radiopharmaceuticals
Slide 33: Pre-targeting Rationale: Current Radiopharmaceutical State of the Art
Pre-targeting Rationale: Current Radiopharmaceutical State of the Art Peptide-based radiopharmaceuticalsare the most successful commercial radioligand products + Peptide and peptide-tike small molecules + Rely on fast clearance from the body to reduce radiation dose to non-target tissues + Typically
Slide 34: Pre-targeting Rationale: mAbs Have Significant Role in Cancer Therapy
Pre-targeting Rationale: mAbs Have Significant Role in Cancer Therapy ‘Antibody Drug Conjugates (ADCs) are a successful high-growth product class but mAbs are not deal radiopharmaceuticals, + FDAhas approved over 100 mAbs: 9 of the top 20 therapeutic products worldwide with more than $75 billion in
Slide 35: of mAbs, but re
of mAbs, but re ) PERSPECTIVE
Slide 36: Tumor Targeting Properties of mAbs are Ideal for Accumulation on Target
Tumor Targeting Properties of mAbs are Ideal for Accumulation on Target (but slow) Representative imagingacross longer time frame demonstrates clearance and uptake kinetics Long circulation time with tittle tumor uptake for the first 24 8d High accumulation of mAb onto tumor with clearance from bloo
Slide 37: Pre-targeting Platform: Combining the Best of mAbs and Small Molecules/Peptides
Pre-targeting Platform: Combining the Best of mAbs and Small Molecules/Peptides Relieson the different kinetics of large proteins and small molecules or peptides and a multi-step process © raminister cota moaited monoctonat antibody or targeting protein © wer severat days, mab wit have accumulated o
Slide 38: Promise of Pre-Targeted Approach - Clinical Data
Promise of Pre-Targeted Approach - Clinical Data GaIMP288 - Images > 24 hours following Anti-CEA Bispecific mAb’ Immuno-PET/CT with anti-CEA BsmAb_ and °Ga-IMP288 peptide showing pathological lesions with heterogeneous SUVmnax FANging from 3.0 to 20.1 Maximum-intensity-projection (MIP) image (A) sho
Slide 39: State of the Art in Pre-Targeting for Radiopharmaceuticals
State of the Artin Pre-Targeting for Radiopharmaceuticals Reviewof currentstate of the art technology platforms Clinically Evaluated (Phase | / Il) A Bispecific Antibody — Hapten (eg SADA) Not Mostar ge 7 8 Streptavdin-Biotn Immunogen ena Preciinically Evaluated only Current state of the art Oligonu
Slide 40: Perspective Pre-Targeting Platform: Host-Guest Chemistry
Perspective Pre-Targeting Platform: Host- Guest Chemistry After exhaustivereview of State of the Art, Perspective chose CB7 (Host) - Adamantane (Guest) System GUEST | Anideal pretargetingagent High in vivo stability R +O Modular Non-toxic Cucurbit{7Junl (C87) modified _-—-Adamantane antibody (mAb) R
Slide 41: Pre-Targeting Platform: Host-Guest Chemistry and in vivo Experiment
Perspective Pre-Targeting Platform: Host- Guest Chemistry and in vivo Experiment ‘Synthesized the Guest as an adamantane-PEG3-PSC (Perspective's proprietary chelator) ae SF macs | 9 em ae ty Sper fe en yA mie PA meas MRI O) zpsenes ese (enmeneeracen'| Firstin vivo Experiment: Observations + 6-day la
Slide 42: Pre-Targeting Platform: Host-Guest in vivo Imaging Experiment
Perspective Pre-Targeting Platform: Host- Guest Chemistry in vivo Imaging Experiment Representative maximum intensity projection images of ligand during optimization process 4 hours post guest 8 hours post guest 24 hours post guest 2 22 34 0 0 PERSPECTIVE
Slide 43: Pre-Targeting Platform: Significant Opportunity to Expand into ADC space
Perspective Pre-Targeting Platform: Significant Opportunity to Expand into “ADC” space ‘Vast number of mAb targets and ligands available to exploit Expansive Range of Targets Available Many mAbs with Clinical Data + Bosietal.,£J Cancer2023 + Vast number of mAbs that are humanized and have been in hu
Slide 44: Clinical Programs: VMT-a-NET and VMT01
Clinical Programs: VMT-a-NET and VMT01 Safety Update from Dose Escalation Studies
Slide 45: Neuroendocrine and SSTR2+ Tumors: VMT-a-NET
Neuroendocrine and SSTR2+ Tumors: VMT-a-NET Phase | Dose Escalation Recruitment and Safety Update
Slide 46: VMT-a-NET Development Status
VMT-c-NET Development Status Targeting somatostatin receptor type 2 (SSTR2) for the imagingand treatment of neuroendocrine tumors with possible expansion into other SSTR2+ tumor types Initiated therapy (2022) under compassionate use in India - complete data of 12 patients to be presented at SNMMI in
Slide 47: Clinical Investigation of VMT-a-NET in Metastatic SSTR2 Positive Patients
Clinical Investigation of [72Pb]VMT-c-NET in Metastatic SSTR2 Positive Patients Interim Results in 10 of 12 patients as of September 28. 2023. for Ongoing Investigationin India Current Status + Patients with prior lines of therapy. late-stage, anatomically S™"@Y Treating Physician: different NETS (m
Slide 48: High Partial Response Rate at Starting Dose in Late-Stage NETs
High Partial Response Rate at Starting Dose in Patients with SSTR+, Late-Stage NETs Interim Results as of September 28, 2023, for Ongoing Clinical Investigation Program in India = Ox Patents A * @ —exreeesy Po ak Pens ox exp mincasn ok nner ex Patent 4 Ox > PR (RECISH) vere peer Ox Patient 7 ak? PR
Slide 49: Trial Design: VMT-a-NET Phase 1/2a For Neuroendocrine Tumors
Trial Design: [2!2Pb]VMT-o-NET mTPI-2! Phase 1/2a For Neuroendocrine Tumors ‘SGLC} also possible PrimaryObpatne: To determine the MTO/MFO of PSPONMFGNET(RP2D)| Imei FDA proved SSTR2 PET/CT ion rn 25-10 mi dose escalation wih fed dosngevey peat Unresecabe or metastatic SSTR2 postive NETS Estinted Ten
Slide 50: VMT-a-NET Treatment Emergent Adverse Events by CTCAE Grade
VMT-o-NET Treatment Emergent Adverse Events by CTCAE! Grade as of March 7, 2024 Grades | Grade2_| Grade Total numbor ofTEAES 24 3 1 3 Alopecia Diarhes Fatigue Lethaney ‘Abdominal pain Dry mouth _ Dyspepsia Eger iby pedal edema onthe left foot Elevated amylase Elevated AST Eloyted bilirubin Gost Head
Slide 51: Summary VMT-a-NET Trial Status and Safety Update
Summary VMT-c-NET Trial Status and Safety Update as of March 7, 2024 StudyStatus SafetyUpdate * T sites active, additional sites in feasibility + Safety Review Committee after Cohort 1 assessment unanimous agreement to escalate dose + High level of interest by clinicians and patients Total Treatment
Slide 52: Metastatic Melanoma: VMT01
Metastatic Melanoma: VMT01 Phase | Dose Escalation Recruitment and Safety Update
Slide 53: Slide 53
Slide 54: Trial Design: VMT01 Phase 1/2a For Metastatic Melanoma
Trial Design: [2“2Pb]VMT01-T104 mTPI4 Phase 1/2a For Metastatic Melanoma PrimaryObjpctive: To determine the MTO/MFD of PUNATOL (RPZO) | Imaging (PPUIVNTOR SPECT/CT or (oayvntToe PET/CT 8 15.mC\ dose escalation of f2PHVMTOL wih Enoll-52 subjects ‘Whersoniienoon ied dosing every 8 weeks for upto 3 ees
Slide 55: VMT01 Treatment Emergent Adverse Events by CTCAE Grade
VMTO1 Treatment Emergent Adverse Events by CTCAE Grade as of March 7, 2024 Total nuber of TEAES Nausea Iymphosje court deceased Hyponataeri ‘aSTcre3se3 Contusion| ‘omo-s6 Denness. Hypoaibumnaamia Hyporoiaema Infusion te eravasabon terraioal noomal26 ai] Wee Muste spasms Pann every Patel count crease
Slide 56: Summary VMT01 Trial Status and Safety Update
Summary VMTO1 Trial Status and Safety Update as of March 7, 2024 Study Status Safety Update * S sites active, additional sites in feasibility + Safety Review Committee after Cohort 1 assessment unanimous agreementto escalate dose + High level of interest by clinicians and patients + Total Treatment
Slide 57: Summary of Current Safety Evaluation of VMT-a-NET and VMT01
Summary of Current Safety Evaluation of VMT-o-NET and VMTOL + Both programs have completed Cohort 1 and continue to enroll in their respective Cohort 2 + No DLTs were observedacross either program + Except for G3 diarrhea. only G4 and G2 AES have occurred + Dose escalation is ongoing * Preliminary s
Slide 58: Combination Targeted Alpha Particle Therapy & Immunotherapy
Combination Targeted Alpha Particle Therapy & Immunotherapy Clinical Collaboration Agreement with Bristol Myers Squibb signed for OPDIVO® (nivolumab) supply March 2024 Combination with Standard of Care Immunotherapy ICl-resistant B16 F.10 Murine Melanoma Model* 100: + In melanoma, immune checkpoint
Slide 59: Phase 1 Amendment: VMT01 in Combination with Nivolumab
Phase | Amendment: [?*7Pb]VMTO1 in Combination with Nivolumab - Sequential Design ‘To determine the MTO/MED of !°Pb]VMTOL (R20) in Primary Object: combination with PO inhibitor (nvotumab) ba iPaymrcasregar 3 15 mGidose esaatin of =PHVMTOL wth Enroll -82 subjects “ThorapoutieDose {ued dosing every 8
Slide 60: KOL Discussion
KOL Discussion Richard L. Wahl, MD Professor of Radiology and Radiation Oncolog Washington University School of Medicine
Slide 61: Trends in Radiopharmaceutical Therapy (RPT)
Trends in Radiopharmaceutical Therapy (RPT) What is most exciting to you?
Slide 62: Growth in Radiopharmaceutical Therapy Published Research
Growth in Radiopharmaceutical Therapy Published Research Publications peryear related to RPT by cancer type Publications peryear by isotope emission profile = = ‘Number of publications Ama
Slide 63: Alpha and Beta RPT
Alpha and Beta RPT The differences, opportunities and challenges
Slide 64: VMT-a-NET Shows Significant Improvement vs Standard of Care in Preclinical Models
VMT-o-NET Shows Significant Improvement vs Standard of Care in Preclinical Models ‘Superior Efficacy with Single Dose or Multiple Administrationsin AR42J SSTR2-Expressing Tumor ‘Standard of Care| (PD VMT-aNET (4x30pC)
Slide 65: Mythbusting: Daughters from Ac-225 don't redistribute
Mythbusting: “Daughters from 22°Ac-225 don't redistribute” 2540 daughter redistribution - ACTION-1 trial measurement of early and late gamma emissions from healthy tissue Early (241) and Late 228) Normal organs 2'Fr | Normal organs 2B) | | ean Pe peas ; iS o ale | = 4 o Sas + Extrapolations for radi
Slide 66: Mythbusting: Pb-212 Doesn't Get Enough Energy Into the Tumors
Mythbusting: ““2Pb Doesn't Get Enough Energy Into the Tumors” 212Pp isa “high dose rate” alpha emitter witha short half life - energy is deposited rapidly to tumor and then gone Delivering alphas faster whilst drug and isotope ‘tumor retention is high enables a better therapeuticindex: greater effic
Slide 67: Why are NETs and prostate cancer the big winners in targeted RPT?
Why are NETs and prostate cancer the big winners in targeted RPT? Can we improve on currently approved products?
Slide 68: A few molecular targets have dominated radiopharmaceutical therapy
A few molecular targets have dominated radiopharmaceutical therapy aan on Ae
Slide 69: PSMA-directed RPT today binds to lacrimal and salivary gland tissue
PSMA-directed RPT today binds to lacrimal and salivary gland tissue 68Ga-PSMA-14-PET2 Adverse side effects of salivary and lacrimal gland uptake of PSMA-RPT compounds + Xerostomia (dry mouth) * Difficulty swallowing + Loss of taste * Dental decay + Keratoconjunctivitis sicca (dry eyes)
Slide 70: What can be learned from compassionate use studies?
Whatcan be learned from compassionate use studies? How do the results impact how patients and doctors view the field?
Slide 71: High Partial Response Rate at Starting Dose in Late-Stage NETs
High Partial Response Rate at Starting Dose in Patients with SSTR+, Late-Stage NETs Interim Results. as of September 28, 2023, for OngoingClinical Investigation Program in India * er Pasa ox “ESS kent ak Patents ox raincash Kner Oxi Panes ox raises ve keener Ox Pont a *> paipien ° 4 8 2 16 20 2 28 2
Slide 72: Do you see a future for RPT in combination with other oncology drugs?
Do you see a future for RPT in combination with other oncology drugs? Melanoma and beyond
Slide 73: Ga-68 VMT02 PET Imaging in Patient with MC1R Positive Metastatic Melanoma
[®Ga]VMT02 PET Imaging in Patient with MC1R Positive Metastatic Melanoma Diagnostic Peptide Demonstrates Similar Uptake to FDG in Tumors 35F-FDG (Standard of Care) {®Ga]vmro2 Patient information: + Male, Asian, 33 years old + [68Ga]VMTO2: 7 mci injection. 45 min post- injection imaging Clinical Coll
Slide 74: Combination Targeted Alpha Particle Therapy & Immunotherapy
Combination Targeted Alpha Particle Therapy & Immunotherapy Clinical Collaboration Agreement with Bristol Myers Squibb signed for OPDIVO® (nivolumab) supply March 2024 Combination with Standard of Care Immunotherapy ICl-resistant B16 F.10 Murine Melanoma Model* 100: + In melanoma, immune checkpoint
Slide 75: Mythbusting
Mythbusting 212Pb and Other Alphas
Slide 76: Mythbusting: Pb-212 Doesn't Get Enough Energy Into the Tumors
Mythbusting: ““2Pb Doesn't Get Enough Energy Into the Tumors” 212Pp isa “high dose rate” alpha emitter witha short half life - energy is deposited rapidly to tumor and then gone Delivering alphas faster whilst drug and isotope ‘tumor retention is high enables a better -eomoriaaisepyyaay erie cote ef
Slide 77: Manufacturing Update
Manufacturing Update Scaling Finished Radiopharmaceutical Production
Slide 78: Mythbusting: Regulatory environment doesn't suit Pb-212
Mythbusting: “Regulatory environment doesn’t suit 22Pb” Manufacturingregulations are clearand practical for production of Pb radiopharmaceuticals PET Manufacturing Radiotherapeutic Manufac * Licensed at the state level under the» Licensed at the Federal level under 21 J+ Licensed cGMP under 21. CFR
Slide 79: Accelerated Expansion of Manufacturing Capabilities: Build and Partner
Accelerated Expansion of Manufacturing Capabilities: Build and Partner + Purpose-built factory equipped to process high energy, high activity production + Leverage an extensive portfolio against large scale production within a single facility Vertical + Uulze internal expertise for Pb to design batc
Slide 80: Acquisition of GMP Facility in Somerset, NJ
Expansion of Manufacturing Capabilities: Acquisition of GMP Facility in Somerset, NJ Former AZEDRA® facilityacquired from Lantheus March 2024 st production for clini and early comme le up + Acquisition of 3 Part 211 compliant manufacturing suites with additional clinical suite + On-boarding of 24 ta
Slide 81: Slide 81
Slide 82: Slide 82
Slide 83: Slide 83
Slide 84: Slide 84
Slide 85: Slide 85
Slide 86: Slide 86
Slide 87: Slide 87
Slide 88: Slide 88
Slide 89: Slide 89
Slide 90: Slide 90
Slide 91: Slide 91
Slide 92: Slide 92
Slide 93: Slide 93
Slide 94: Slide 94
Slide 95: Slide 95
Slide 96: Slide 96
Slide 97: Slide 97
Slide 98: Slide 98
Slide 99: Slide 99
Slide 100: Slide 100